[
  {
    "ts": "2025-12-30T22:38:34+00:00",
    "headline": "Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves",
    "summary": "Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target. The firm launched coverage of the specialty pharmaceuticals industry with a neutral view, noting that investor sentiment is […]",
    "url": "https://finance.yahoo.com/news/barclays-initiates-viatris-vtrs-overweight-223834256.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9e41c824-32c9-3e30-96c6-df36f8d035df",
      "content": {
        "id": "9e41c824-32c9-3e30-96c6-df36f8d035df",
        "contentType": "STORY",
        "title": "Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves",
        "description": "",
        "summary": "Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target. The firm launched coverage of the specialty pharmaceuticals industry with a neutral view, noting that investor sentiment is […]",
        "pubDate": "2025-12-30T22:38:34Z",
        "displayTime": "2025-12-30T22:38:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/74fb705bb9c3ce561b1e73c01a8c0ec6",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGSUgQWY1mvU5iiUFvOJaw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/74fb705bb9c3ce561b1e73c01a8c0ec6.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pOwRcCLvUVYudHrb3ECDAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/74fb705bb9c3ce561b1e73c01a8c0ec6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-initiates-viatris-vtrs-overweight-223834256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-initiates-viatris-vtrs-overweight-223834256.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "BCS"
            },
            {
              "symbol": "BIOCON.BO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]